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Background: Meticillin-resistant Staphylococcus aureus (MRSA) is frequently endemic in
healthcare settings and may be transmitted by person-to-person spread. Asymptomatic
MRSA carriers are potential, unsuspected sources for transmission and some of them may
be identified by admission screening.
Aim: To assess whether rapid point-of-care screening (POCS) for MRSA at hospital admis-
sion may be associated with a reduction in MRSA acquisition rates when compared with
slower laboratory-based methods.
Methods: A cluster-randomized cross-over trial was conducted in four admission wards of
an acute London tertiary care hospital. Polymerase chain reaction-based POCS screening
was compared with conventional culture screening. Patients were screened on ward
admission and discharge, and the MRSA acquisition rate on the admission wards was
calculated as the primary outcome measure.
Results: In all, 10,017 patients were included; 4978 in the control arm, 5039 in the POCS
arm. The MRSA carriage rate on admission was 1.7%. POCS reduced the median reporting
time from 40.4 to 3.7 h (P < 0.001). MRSA was acquired on the admission wards by 23
(0.46%) patients in the control arm and by 24 (0.48%) in the intervention arm, acquisition
rates of 5.39 and 4.60 per 1000 days respectively. After taking account of predefined
confounding factors, the adjusted incidence rate ratio (IRR) for change in trend for MRSA
acquisition was 0.961 (95% confidence interval: 0.766e1.206). The adjusted IRR for step
change for MRSA acquisition was 0.98 (0.304e3.162).
Conclusion: POCS produces a significantly faster result but has no effect on MRSA acqui-
sition on admission wards compared with culture screening. Where compliance witht of Microbiology, King’s College Hospital NHS Foundation Trust, London SE5 9RS, UK. Tel.: þ44 020
. Jeyaratnam).
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impact on MRSA acquisition rates over the first one to four days of admission compared
with conventional culture screening.
ª 2016 The Authors. Published by Elsevier Ltd
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Meticillin-resistant Staphylococcus aureus (MRSA) infections
are associated with greater mortality, morbidity, and health-
care costs than are similar infections with meticillin-
susceptible strains.1 MRSA is frequently endemic in health-
care settings and may be transmitted by person-to-person
spread. Asymptomatic MRSA carriers are potential, unsus-
pected sources for transmission and some of them may be
identified by admission screening.1
In England and Wales, the Health Act (2008) Code of Practice
for the prevention and control of healthcare-associated in-
fections requires hospitals to have policies for MRSA admission
screening and care pathways for the management of MRSA
carriers.2 The identification, isolation, and decontamination of
patient carriers are associated with reduced MRSA transmission,
although the evidence for this is limited and debated.3e7
Conventional laboratory-based culture screens (CS) take two
or three days to report a result. More rapid detection of MRSA
carriers theoretically should lead to faster implementation of
control procedures and reduce the transmission of MRSA.
Screening tests for MRSA using laboratory-based polymerase
chain reaction (PCR) have significantly faster turnaround times
to result, averaging 22 h.8 However, although some studies
comparing rapid and conventional screening at the same
anatomical sites (the majority with nasal screens only) have
shown an association between the use of laboratory-based PCR
tests and a reduction in MRSA transmission and acquisition
rates, others have not.4,7e12 The lack of effect in some studies
may be because of continuing cross-transmission of MRSA during
the 22 h delay before receiving the result of the laboratory-
based PCR test. Much of that delay is due to the transit of the
specimen between the ward and the laboratory. Because of the
conflicting outcome results and the greater expense compared
with CS, laboratory-based PCR tests have not been recom-
mended for routine adoption in English hospitals.13
Point-of-care MRSA PCR screening tests (POCS) can be per-
formed on the ward, eliminating specimen transit times and
allowing a truly rapid result within about 1 h. There have been
no reports of controlled studies on this method. We therefore
conducted a clinical trial e on hospital wards where a good
standard of infection prevention and control was in place e to
determine whether performing POCS is associated with a
reduction in MRSA acquisition rates compared with CS.
For elective admissions, MRSA screening (and decontami-
nation if necessary) is best done before hospital admission in
outpatient clinics where rapid screening is unnecessary. Rapid
screening is more appropriate for emergency admissions. In
order to achieve better patient management, safety, and
resource utilization, many hospitals, including our own, have
introduced admission wards. Emergency patients are admitted
to these wards for review, investigation, and stabilization
before being transferred to general wards or discharged toet al., Point-of-care universa
ital Infection (2016), http://doutpatient care.14 Stay on these wards is usually around
24e36 h. MRSA screening of emergency hospital admissions is
therefore ideally done on the admission wards. Since POCS
can produce results within 1 h, whereas CS takes two or three
days, POCS will identify the MRSA status of patients before
transfer or discharge and theoretically reduce transmission
and acquisition within the general wards. Furthermore, since
the postulated advantage of POCS is to reduce the 24e36 h
delay of culture screening, POCS should theoretically reduce
MRSA transmission/acquisition on the admission wards
themselves.
The impact of admission ward screening on MRSA acquisition
on general wards is dependent on numerous uncontrolled fac-
tors (including MRSA carriage by elective admissions and gen-
eral ward transfers) and is difficult or impossible to measure
with any accuracy. By contrast, the impact of rapid admission
ward screening on MRSA acquisition within the admission wards
themselves can be measured fairly accurately by screening at
admission and on transfer/discharge and controlling for other
variables by using a cross-over trial design. If POCS does have
an impact on MRSA transmission compared with CS, then this
should occur during the 22e36 h stay on the admission wards; if
it has no effect during this period then it will have no advantage
over culture- or laboratory-based PCR screening. We therefore
performed a controlled cluster-randomized cross-over clinical
trial of POCS compared with CS on the four admission wards in
our hospital, with MRSA acquisition on the admission wards as
the primary outcome.
Methods
Setting
The study was performed in a 900-bed, acute National
Health Service (NHS) London teaching and tertiary care hospi-
tal between May 2011 and July 2012. Patients are admitted
from the emergency department on to one of four admission
units. After a period of assessment and treatment on these
units, they are either discharged from the hospital or admitted
to a general ward. For this study we screened patients on
arrival at the admission wards, which were the two medical
admissions units, the acute surgical unit, and a neurosurgical
ward, the only study ward with a high dependency unit. The
characteristics of the wards are shown in Table I.
A cluster-randomized, controlled cross-over trial design
was used, with the four wards as clusters, randomized to
control arm and intervention arm by a computer-generated
randomization list. After the first phase of seven months,
there was a washout period for one month, followed by a
second phase of seven months, in which the wards were
crossed over (Figure 1). Assuming a 3% MRSA carriage rate and
a 0.3 transmission rate, we estimated that a sample size of
3840 patients per study arm would have an 80% power (at thel screening for meticillin-resistant Staphylococcus aureus: a cluster-
x.doi.org/10.1016/j.jhin.2016.08.017
Table I
Characteristics of study wards
Ward specialty No. of beds
in bays
Side
rooms
Total
beds
Acute surgical unit
(six bays)
28 3 31
Medical admissions
unit 1 (six bays)
24 6 30
Medical admissions
unit 2 (six bays)
24 6 30
Neurosurgical ward with
high dependency
unit (four bays)
21 10 31
P.J. Wu et al. / Journal of Hospital Infection xxx (2016) 1e8 35% significance level) to detect a 58% reduction in transmission
rate, from 0.3 to 0.126.
Ethics
In accordance with ethical committee approval, all
admitted patients were eligible for inclusion after providing
informed verbal consent. Staff performing the screening were
trained in how to obtain consent and understood that patients
could refuse. (NHS Research Ethical Committee number: 09/
H0709/68; clinical trial registration: ISRCTN35178384.)
Intervention and control arms
During the control phase, admission screening was by CS
only. During the intervention, patients were screened by both
CS and POCS and results were reported as soon as they were
available. If the POCS returned an error/invalid result, the test
was not repeated and interpreted as ‘not positive’.
For CS, pooled swabs from nose, throat, and perineum were
cultured in MRSA selective broth and MRSA Chromagar (Oxoid,
Basingstoke, UK). Swabs from lesions at other sites were pro-
cessed similarly. Meticillin susceptibility was determined by
disc or automated testing (Vitek2; bioMe´rieux, Basingstoke,
UK).
The intervention was POCS using the Xpert MRSA system
(Cepheid, Sunnyvale, CA, USA). A four-module Xpert system
was installed in each of the study wards and POCS was per-
formed by ward healthcare workers (HCWs) after training and
confirmation of competency. Nasal swabs only were used for
POCS, since these are the specimens licensed by the US Food &
Drug Administration for the system. Two nasal samples were
taken simultaneously with double-headed swabs (Copan,
Brescia, Italy); one was used for CS and the other for POCS.
Patients’ MRSA discharge status was assessed by CS on pooled
nose, throat, and perineum swabs.
Standard infection prevention and control (IPC) pre-
cautions were implemented for all patients, as well as pre-
emptive isolation of patients judged at risk of MRSA car-
riage.12,15 MRSA-positive patients were entered into an MRSA
care pathway if they were known to be previously positive or
as soon as a positive result was obtained from either POCS or
CS; the management included decontamination and isolation
(in side room, cohort bays, or barrier isolation on wards,
depending on the facilities available), following national
guidelines.1,15Please cite this article in press as: Wu PJ, et al., Point-of-care universa
randomized cross-over trial, Journal of Hospital Infection (2016), http://dData collection
We collected patient demographics, date and time of
admission and discharge, and physical status on admission
[using the American Society of Anesthesiology (ASA) scoring
system].16 We collected potential ward confounding factors for
MRSA transmission, including staffing levels; staff hand hygiene
policy compliance (observed monthly); patient-days per month
that MRSA-positive patients were cohort/barrier-isolated; and
the MRSA importation pressure, defined as the proportion of
patients positive for MRSA on admission per month.
We regarded MRSA culture screening specimens taken
within 48 h of admission and 48 h after discharge as valid
screens for the study. Patients who stayed for <48 h were
included only if both admission and discharge culture screens
were performed during their ward stay. Patients who were
MRSA culture positive in any specimen taken up to five days
before admission were classified as MRSA admission positive.
Outcome measures
The primary outcome was the MRSA acquisition rate (the
proportion of patients MRSA negative on admission who subse-
quently became MRSA positive by the time of discharge). Sec-
ondary outcomes were (i) the MRSA transmission rate (the ratio
of patients MRSA positive on admission to the number of MRSA
acquisitions); (ii) the MRSA acquisition rate per 1000 patient-
days; (iii) the turnaround times for the screening tests; and
(iv) the performance characteristics of POCS compared with CS.
Statistical analysis
To assess the effect of the intervention on the primary
outcome, we conducted a multi-level Poisson segmented
regression allowing for ward-level random variation for baseline
levels and time trends (from study start to end). Step changes
and changes in trends of MRSA acquisition rates per 100 patients
at risk were assessed in amodel with a log link function adjusted
by potential confounders (treated as continuous variables). An
offset term was included in the natural logarithm scale to ac-
count for the monthly exposure in each ward [i.e. the total
number of patients at risk of acquiring MRSA (MRSA negative on
admission) who were discharged monthly]. The dependent var-
iable was themonthly number of patients negative on admission
who acquired MRSA during the ward stay. The significance of
fixed effects was assessed through Wald tests. Measures of as-
sociation for the fixed terms were summarized by adjusted
incidence rate ratios per 100 patients at risk. The maximal
randomeffect structure justified by the datawas determined by
comparing models accommodating increasingly complex
randomstructures through log likelihood ratio tests.Theanalysis
was conducted in R-3.1.1. statistical software using the package
‘glmmADMB’ to fit multi-level models by Laplace approx-
imation.17e19 For robustness,model coefficientswerecompared
to those obtained using the Penalized Quasi-Likelihood estima-
tion method (glmmPQL) in the ‘MASS’ package.20,21
Results
There were 13,715 admissions to the study wards, 6680
(48.7%) in the control arm and 7035 (51.3%) in the interventionl screening for meticillin-resistant Staphylococcus aureus: a cluster-
x.doi.org/10.1016/j.jhin.2016.08.017
Control arm (ASU and MAU1)
Patients admitted and assessed for eligibility (n = 3741)
Intervention arm (ASU and  MAU1)
Patients, admitted and assessed for eligibility (n = 3952)
Not swabbed on admission
and not known MRSA
positive (n = 226, 6.0%)
MRSA admission status,
culture only
(n = 3515, 94.0%)
MRSA admission status,
culture only
(n = 2704, 92.0%)
Intervention arm (NSW/HDU and MAU2)
Patients admitted and assessed for eligibility (n = 3083)
Control arm (NSW/HDU and MAU2 )
Patients admitted and assessed for eligibility (n = 2939)
Not swabbed on admission
and not known MRSA
positve (n = 71, 2.3%)
Not swabbed on admission
and not known MRSA
positve (n = 228, 5.8%)
(n = 140; 5.4%)
MRSA admission status,
culture only
(n = 3012, 97.7%)
MRSA admission status,
culture only
(n = 3724, 94.2%)
MRSA culture positive*
(n = 73, 2.1%)
MRSA culture positive*
(n = 40, 1.5%)
MRSA culture positive*
(n = 52, 1.7%)
MRSA culture positive*
(n = 57, 1.5%)
MRSA culture negative
(n = 2960, 98.3%)
MRSA culture negative
(n = 3667, 98.5%)
MRSA culture negative
(n = 3442, 97.9%)
Lost to follow-up
(n = 698, 20.3%)
Lost to follow-up
(n = 430; 16.2%)
Discharge sample accepted
(n = 2744, 79.7%)
Discharge sample accepted
(n = 2234, 83.8%)
Discharge sample accepted
(n = 2207, 74.6%)
Discharge sample accepted
(n = 2832, 77.2%)
MRSA culture
positive
at discharge (n = 14)
MRSA culture positive
at discharge (n = 9)
MRSA culture negative
at discharge (n = 2730)
MRSA culture negative
at discharge (n = 2225)
MRSA culture negative
(n = 2664, 98.5%)
MRSA culture negative
at discharge (n = 2195)
MRSA culture negative
at discharge (n = 2820)
MRSA culture positive
at discharge (n = 12)
MRSA culture positive
at discharge (n = 12)
Lost to follow-up
(n = 753, 25.4%)
Lost to follow-up
(n = 835, 22.8%)
Crossover
Phase 2
Phase 1
Not swabbed on
admission and not known
MRSA positive
(n = 235, 8.0%)
*Patients with any MRSA culture-positive specimen taken up to five days before  hospital admission
or 48 h after admission to study wards or transfer of  MRSA-positive patients between hospitals
Figure 1. Flow chart of the cross-over trial. ASU, acute surgical unit; NSW/HDU, neurosurgical ward with high dependency unit; MAU1,
medical admission unit 1; MAU2, medical admission unit 2; MRSA, meticillin-resistant Staphylococcus aureus.
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and were excluded, leaving a total of 12,955 patients in the
study, 6219 in the control, and 6736 in the intervention arm
(Figure 1). Of this remaining total, 222 (1.7%) were CS positive
for MRSA on admission (or were known to be positive within the
five days before admission) (control 113, 1.8%; intervention
109, 1.6%). POCS was performed on 6414 intervention arm
admissions (91.2% of total admissions).
With CS as the reference standard, the sensitivity of POCS
was 68.8%, specificity 97.2%, positive predictive value 28.8%
and negative predictive value 99.5%. Error/invalid results
occurred in 6.2% of tests and were excluded from this analysis.
The median turnaround time from admission to reporting was
40.4 h for CS and 3.7 h for POCS (P < 0.001).
Of the 12,733 patients who were MRSA culture negative on
admission, 2716 (21.3%) were not correctly swabbed at
discharge, due to an oversight by staff or by patients leaving
the ward before the swabs were taken (control 1128, 18.5%;
intervention 1588, 24.0%). Thus, 10,017 patients were CS
negative on admission, had CS on discharge and were eligible
for analysis (78.7% of all admissions screened by CS), 4978
control (81.5%) and 5039 intervention (76.0%) (Figure 1). The
baseline patient and ward characteristics of patients in the two
study wards were similar (Table II).Table II
Baseline characteristics of all patients in the control and inter-
vention wards
Characteristics Control wards Intervention wards
Median (IQR) age in years 57.2 (40.3e75.4) 58.7 (41.0e76.5)
Women 3155 (47.2%) 3367 (47.9%)
Median (IQR) ASA scorea 2 (2e3) 2 (2e3)
Median (IQR) study ward
stay in days
1.9 (1.0e3.6) 2.0 (1.0e3.7)
No. of patients screened
on admission or known
to be MRSA positive
6219 6736
No. of patients MRSA
positive at admission
(% of screened
admissions)
113 (1.8%) 109 (1.6%)
MRSA culture positive on
admission but pre-
emptively isolated
before positive result
(% of all positives)
33 (29.2) 48 (44.0)
Median (IQR) study ward
stay for patients who
are MRSA culture
positive on admission
2.0 (0.9e4.9) 3.0 (1.3e4.9)
No. of patient-days on
which MRSA-negative
patients were at risk of
MRSA acquisition
20,956 23,704
ASA, American Society of Anesthesiology; IQR, interquartile range;
MRSA, meticillin-resistant Staphylococcus aureus.
All differences between the control and intervention wards were non-
significant.
a ASA score for physical status: from 1 (completely healthy) to 5
(moribund, not expected to live 24 h).16
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eligible for analysis, 23 out of 4978 (0.46%) patients in the
control arm and 24 out of 5039 (0.48%) in the intervention arm
(Table III).
The total number of days on which MRSA-positive admitted
patients were not isolated was 257 (67% of their total stay of
378.3 days) in the control arm and 205 (40.6% of their total stay
of 504.8 days) in the intervention arm (P < 0.001).
There was no significant difference between patients in the
control and intervention arms for age, gender, ASA score, study
ward stay, days at risk for MRSA acquisition, being MRSA culture
positive on admission but pre-emptively isolated before the
positive result, or length of ward stay of patients who were
MRSA culture positive on admission. The segmented Poisson
regression results showed that none of the confounding ward
variables was a significant predictor of MRSA acquisition rate
and no step change or trend change in MRSA acquisition rate
was observed following the intervention. The results were
consistent with those obtained when using the Penalized Quasi-
Likelihood estimation method (data not shown).
Seven patients who were MRSA culture negative on admission
andpositiveondischargewerePOCSpositiveonadmission.When
these cases were excluded from the analysis, there was
still no difference in the acquisition rates between the two arms.
Discussion
As in many other hospitals, we now have four acute admis-
sion wards for the initial admission and assessment ofTable III
MRSA acquisition and transmission rates
Variables Control arm Intervention arm Total
No. of patients
who underwent
laboratory
culture
screening on
admission (or
who were known
to be positive)
and discharge
4978 (74.5%) 5039 (71.6%) 10,017
No. of patients
MRSA positive by
laboratory
culture
screening on
admission (or
who were known
to be positive)
113 (1.8%) 109 (1.6%) 222 (1.7%)
No. of patients
who acquired
MRSA by
discharge (MRSA
acquisition rate)
23 (0.46%) 24 (0.48%) 47 (0.47%)
Acquisition per
1000 patient-
days
5.39 4.60 4.97
Transmission rate 0.20 0.22 0.21
MRSA, meticillin-resistant Staphylococcus aureus.
l screening for meticillin-resistant Staphylococcus aureus: a cluster-
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(mean: 2 days) before being discharged home or transferred to
general wards. Admission MRSA screening of emergency pa-
tients is therefore ideally done on admission to the admission
wards. Because conventional CS takes two or three days, some
CS results become available only after patients have left the
admission ward. Rapid POCS can produce results within about
1 h and is faster even than laboratory-based PCR testing, which
produces results in about 22 h. POCS on admission wards
therefore should theoretically facilitate the efficient man-
agement of MRSA carriers, allowing them to be placed on the
MRSA pathway hours or days earlier than with other screening
methods. This would be expected to reduce MRSA transmission
and acquisition both on the admission wards themselves and
then on the general wards. If POCS does not have an impact on
transmission and acquisition while on the admission ward, it
would have no advantage over CS wherever it is used.
In order to test this hypothesis we performed a controlled
clinical trial to measure the impact of POCS compared with CS
on MRSA acquisition within the admission wards. We did this,
first, because it is impossible to control for the numerous other
factors that affect MRSA acquisition on general wards, and
second, if POCS does have a beneficial effect, it should be
detectable within the first 24e48 h. If it does not, then slower
and cheaper screening methods would be appropriate.
Furthermore, the risk of MRSA acquisition on the admission
wards is significant; in the present study there were about
20,000 patient-hours of exposure to potential MRSA acquisition
in each of the study arms.
We used a cluster-randomized cross-over study to compare
CS and POCS (the intervention) screening on the four admission
wards. The POCS test was implemented satisfactorily by HCWs,
with performance characteristics similar to those reported by
others.22e25 When compared with CS, the Xpert MRSA speci-
ficity and NPV were high but the sensitivity and PPV were low.
The low PPV result probably reflects a low prevalence of MRSA
carriage at admission; other possible contributory factors
include poor sampling, detection of non-viable organisms,
detection of meticillin resistance genes in other organisms such
as coagulase-negative staphylococci or in gene fragments, or
non-specific amplification.11,26 The extra numbers of MRSA-
positive patients reported by POCS, compared with CS would
have tended to increase rather than decrease early MRSA
control for patients screened by POCS. However, the low
sensitivity of POCS compared with CS reduced the proportion of
CS-positive patients who were detected more rapidly by POCS.
POCS produced significantly faster results than laboratory-
based CS by some 37 h, facilitating the much earlier imple-
mentation of appropriate MRSA control. Thus in the control arm
MRSA-positive patents were isolated for 33% of their total stay
whereas in the intervention arm positive patients were isolated
for 59% of their total stay. The reason the positive patients in
the intervention arm were not isolated for closer to 100% of
their stay was that the POCS test had poor sensitivity (68.8%)
when CS was used as the standard. This meant that around 30%
of the CS-positive patients were not detected by POCS and
were therefore not isolated until the CS result was returned.
Despite there being no significant difference between the
control and intervention arms for patient age, gender, ASA
score, length of ward stay, patient-days at risk of MRSA acqui-
sition or pre-emptive isolation, and allowing for variations in
background MRSA importation pressure, staffing levels, andPlease cite this article in press as: Wu PJ, et al., Point-of-care universa
randomized cross-over trial, Journal of Hospital Infection (2016), http://dcompliance with hand hygiene, there was no significant change
in the MRSA acquisition rate following the intervention. Thus,
we found no evidence to support the hypothesis that rapid POCS
of patients on admission wards reduces rates of MRSA acquisi-
tion, and hence transmission on those wards compared with
conventional, laboratory-based CS. POCS reduced the time
during which MRSA-positive patients were not isolated
compared with CS, but this did not reduce MRSA acquisition.
A cluster-randomized cross-over study was an appropriate
design for this trial but it may have been under-powered. The
MRSA importation pressure and the transmission and acquisition
rates in the control armwere lower than expected and, although
MRSA screening on the admission units best reflects present
hospital practice, it limited the number of clusters for analysis.
Although there were four clusters per arm (the required mini-
mum), a larger number would have been desirable; with each
ward as its own control it was not possible to ensure with four
clusters that the two arms remained balanced over time.
Our study has some limitations. Only about three-quarters
of eligible patients had full admission and discharge screen
data and, although there were about 5000 patients with full
data sets in each arm, it is possible that we were unable to
detect a small effect because rates of both MRSA carriage and
transmission were low. The average length of stay on the
admission wards was about two days and it could be argued
that we may not have detected MRSA transmission by culture
during this period; on the other hand, this is the time during
which POCS would be expected to have a greater impact than
CS. POCS significantly reduced the number of days on which
MRSA positive patients were not isolated compared with CS,
but this effect was reduced by the fact that the sensitivity and
PPV of POCS on nasal swabs compared with CS on pooled
multiple site swabs was low. These low values were partly the
result of the low prevalence of MRSA carriage, but may also
have been because (in culture studies) nasal swabs detect only
around 80% of carriers compared with swabbing at multiple
sites.9 This is an inherent problem with this POCS test because
it is licensed by the FDA for nasal swabs only.
In the present study the MRSA carriage rate at admission
measured by CS was 1.71%. This is much lower than the rate of
6.7% found by CS in London hospitals in 2006e07, but similar to
the 1% result of a one-week national prevalence study of MRSA
screening in English NHS hospitals in 2011.5,8,27 This decline in
MRSA admission carriage reflects the overall fall in MRSA
infection rates in English hospitals associated with a national
programme of targeted improvements in MRSA prevention and
control.13 The lack of effect of rapid POCS in the present study
may have been due to the low MRSA carriage rate at admission
combined with good standard IPC practice, including pre-
emptive isolation of higher-risk patients.
It is likely that in a setting of low MRSA admission preva-
lence, good IPC may prevent most MRSA transmissions, even
without admission screening, whether by standard or rapid
methods.7,10,12 Furthermore, Robotham et al. have shown in
mathematical modelling studies that universal admission and
weekly screening using a PCR MRSA test coupled with isolation
is unlikely to be cost-effective unless the prevalence is high.28
Although the effectiveness of universal MRSA screening of
all admissions has long been debated, the Department of
Health (England) previously recommended that hospitals
should screen all admissions.4e7,29 However, in 2014, the
Department revised its guidance and recommended targetedl screening for meticillin-resistant Staphylococcus aureus: a cluster-
x.doi.org/10.1016/j.jhin.2016.08.017
P.J. Wu et al. / Journal of Hospital Infection xxx (2016) 1e8 7screening of only high-risk patients.13 This view is supported by
the present study, which has shown that there is presently a
very low prevalence of MRSA carriage at admission in London.
In conclusion, there is growing evidence that in an
environment where compliance with appropriate MRSA IPC
procedures is high and where the prevalence of MRSA carriage
is low, rapid MRSA admission screening has no additional impact
on MRSA acquisition and transmission compared with standard
CS. The results of the present trial suggest that this is true not
only for laboratory-based PCR tests but also for very rapid POC
PCR screening. Our study does not support the introduction of
point-of-care MRSA admission screening as a routine.Acknowledgements
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